Eisai
As of the edition of 20 October 2026, Eisai runs 85 drugs, 33 of them marketed; it is on route A at 16 targets and on route B at 30 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 7 company names in this family.
- Mgi Pharma Inc: acquired in 2008; successor EISAI INC
Drugs by status
| Status | Count |
|---|---|
| Marketed | 33 |
| Active | 11 |
| Went quiet | 19 |
| Stopped | 14 |
| Withdrawn from market | 1 |
| Status not established | 7 |
| Total | 85 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Lenvatinib | Ends 2035 (patent) | 3 |
| Decitabine | none listed | 4 |
| Amoxicillin | none listed | 0 |
| Warfarin | none listed | 1 |
| Metronidazole | none listed | 0 |
| Clarithromycin | none listed | 0 |
| Donepezil | none listed | 3 |
| Eribulin | Ended 2026 (exclusivity) | 9 |
| Rabeprazole | none listed | 1 |
| Perampanel | Ended 2026 (patent) | 4 |
| Verapamil | none listed | 8 |
| Avatrombopag | Ends 2032 (exclusivity) | 2 |
| Tazemetostat | Ends 2034 (patent) | 2 |
| Eszopiclone | none listed | 0 |
| Lemborexant | Ends 2031 (patent) | 2 |
| Denileukin diftitox | Ended 2011 (computed from the first US licence) | 0 |
| Pilocarpine | none listed | 2 |
| Fospropofol | none listed | 0 |
| Flecainide | none listed | 0 |
| Iguratimod | none listed | 0 |
| Lecanemab | Ends 2035 (computed from the first US licence) | 1 |
| Rimabotulinumtoxinb | Ended 2012 (computed from the first US licence) | 1 |
| Rufinamide | none listed | 0 |
| Methylcobalamin | none listed | 0 |
| E-7090 | none listed | 3 |
A route B row is one company at one target. 8 more marketed drugs are not listed here.
Where it needs a new molecule
Route A at 16 targets, route B at 30 targets.
All 46 rows on route A or B
In the product46 company-target rows on route A or B; 43 are not shown here, and no score is.
See all 46 targets where Eisai needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 142 trials led
- Nervous system: 97 trials led
- Mental health: 55 trials led